Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    Desferrithiocin is a more potent antineoplastic agent than desferrioxamine

    Access Status
    Fulltext not available
    Authors
    Kicic, Anthony
    Chua, A.C.G.
    Baker, E.
    Date
    2002
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    Kicic, A. and Chua, A.C.G. and Baker, E. 2002. Desferrithiocin is a more potent antineoplastic agent than desferrioxamine. British Journal of Pharmacology. 135 (6): pp. 1393-1402.
    Source Title
    British Journal of Pharmacology
    DOI
    10.1038/sj.bjp.0704507
    ISSN
    0007-1188
    Faculty
    Faculty of Health Sciences
    School
    School of Public Health
    URI
    http://hdl.handle.net/20.500.11937/76835
    Collection
    • Curtin Research Publications
    Abstract

    Desferrithiocin (DFT) is an orally effective Fe chelator, with a similar high affinity and selectivity for Fe to desferrioxamine (DFO), which has been shown clinically to possess antineoplastic activity. In this study, DFT was assessed for antineoplastic potential in hepatocellular carcinoma cell lines (HCC). This was done as there are few treatments for this aggressive neoplasm. The effects of DFT on cell proliferation, cell cycle progression, Fe uptake and toxicity were examined. To establish whether DFT was selective for cancer cells a comparison was made with normal (non-proliferating) hepatocytes and non-tumorigenic (proliferating) fibroblasts (SWISS-3T3). DFT was a potent inhibitor of HCC proliferation (IC50∼40 μM). DFO also inhibited HCC proliferation under the same conditions, but was much less active (IC50 = 110-210 μM). When saturated with Fe, the activity of DFT, like DFO, was greatly diminished, suggesting it may act by depriving the cells of Fe or inactivating essential Fe pool(s). Indeed DFT rapidly decreased Fe uptake from Tf-59Fe by hepatoma cells and also by normal hepatocytes. However, DFT (and DFO) had much less effect on cell survival in hepatocytes and fibroblasts than in hepatoma cells. DFT may, like DFO, inhibit the cell cycle in the S phase of DNA synthesis. Both chelators showed low toxicity. These results indicate that DFT has potent antineoplastic activity in HCC. Further investigation into the DFT class of Fe chelators seems warranted, particularly in view of its high activity in relation to DFO, a chelator which is already in clinical trial for neuroblastoma.

    Related items

    Showing items related by title, author, creator and subject.

    • The desferrithiocin (DFT) class of iron chelators: Potential as antineoplastic agents
      Kicic, Anthony ; Chua, A.C.G.; Baker, E. (2001)
      Iron (Fe) is essential for the proliferation of cancer cells. A subgroup of the orthosubstituted phenolate class of Fe chelators, desferrithiocin [2-(3′-hydroxypyrid-2′-yl)-4-methyl- Δ2-thiazoline-4(S)-carboxylic acid; ...
    • Effect of iron chelators on proliferation and iron uptake in hepatoma cells
      Kicic, Anthony ; Chua, A.C.G.; Baker, E. (2001)
      Background. The siderophore desferrioxamine mesylate (DFO) is used routinely in clinical practice to treat diseases of iron (Fe) overload. Recent studies suggest that DFO and other chelators may have potential in the ...
    • Iron chelators for the treatment of cancer
      Yu, Yu; Gutierrez, E.; Kovacevic, Z.; Saletta, F.; Obeidy, P.; Rahmanto, Y.; Richardson, D. (2012)
      The study of iron chelators as anti-tumor agents is still in its infancy. Iron is important for cellular proliferation and this is demonstrated by observations that iron-depletion results in cell cycle arrest and also ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.